Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234202 · ClinicalTrials.gov registry record · NA
The Effect of a Bioactive Fabric Sleeve
A NA study of Recovery, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT06234202: Active NA study of Recovery, sponsored by Stanford University.
NCT06234202 is a NA study of Recovery that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06234202, a NA study of Recovery, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
In-season pitch volume have been shown to relate to arm soreness in collegiate baseball players. Arm soreness is a common ailment following a pitching appearance due to the adaptation to soft tissue in response to a repetitive load to the throwing arm. Specifically, ongoing and accumulated fatigue and soreness to the flexor pronator mass region of the arm may be a predecessor for UCL injury. Different recovery modalities such as a bioactive fabric sleeve may give pitchers a recovery advantage throughout a baseball season. The primary purpose of this study is to determine if there is a difference in subjective soreness of the flexor pronator mass the day following a game pitching appearance using a sleeve with bioactive fabric which potentially improves cellular function versus a control sleeve.
Primary Outcome
Subjective soreness questionnaires to rank soreness, tightness, and discomfort of the medial forearm on a 1 to 10 scale will be collected throughout the baseball seasons.
Conditions Studied
Interventions
- DEVICE Bioactive Sleeve
- DEVICE Control Sleeve
Study Locations (6)
California
- University of California, Davis - Davis
- University of San Diego - San Diego
- Stanford University - Stanford
Florida
- University of Florida - Gainesville
Virginia
- University of Virginia - Charlottesville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2027-06 |
| Phase | NA |
What the registry record for NCT06234202 still lists
NCT06234202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Recovery appearing as the primary indexed condition, and to 2 interventions - of which Bioactive Sleeve is the first listed.
NCT06234202 lists 6 locations in 4 states (California, Florida, Virginia).
Frequently Asked Questions
What is clinical trial NCT06234202 about?
NCT06234202 is a clinical study titled "The Effect of a Bioactive Fabric Sleeve". In-season pitch volume have been shown to relate to arm soreness in collegiate baseball players. Arm soreness is a common ailment following a pitching appearance due to the adaptation to soft tissue in response to a repetitive load to the throwing arm. Specifically, ongoing and accumulated fatigue a...
What is the current status of trial NCT06234202?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2024-02-16. Estimated completion is 2027-06.
What conditions does trial NCT06234202 study?
This clinical trial studies the following conditions: Recovery.
What interventions are being tested in trial NCT06234202?
The interventions under investigation include: Bioactive Sleeve (DEVICE), Control Sleeve (DEVICE).
Who is sponsoring clinical trial NCT06234202?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234202 being conducted?
This trial has 6 study locations across California, Florida, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recovery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06234202's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI